Myriam Chalabi, Yara L Verschoor, Pedro Batista Tan, Sara Balduzzi, Anja U Van Lent, Cecile Grootscholten, Simone Dokter, Nikè V Büller, Brechtje A Grotenhuis, Koert Kuhlmann, Jacobus W Burger, Inge L Huibregtse, Tjeerd S Aukema, Eduard R Hendriks, Steven J Oosterling, Petur Snaebjornsson, Emile E Voest, Lodewyk F Wessels, Regina G Beets-Tan, Monique E Van Leerdam, Ton N Schumacher, José G van den Berg, Geerard L Beets, John B Haanen
BACKGROUND: Mismatch repair-deficient (dMMR) tumors can be found in 10 to 15% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of neoadjuvant immunotherapy has shown promising results, but data from studies of this approach are limited. METHODS: We conducted a phase 2 study in which patients with nonmetastatic, locally advanced, previously untreated dMMR colon cancer were treated with neoadjuvant nivolumab plus ipilimumab...
June 6, 2024: New England Journal of Medicine